Graham Holdings Company Common Stock vs Moderna, Inc. — how do they compare? Graham Holdings Company Common Stock trades at $1,190.11 (market cap $4.97B), while Moderna, Inc. trades at $223.87 (market cap $86.33B). The key difference: Moderna, Inc. is far larger — about 17.4× Graham Holdings Company Common Stock's market cap, and Graham Holdings Company Common Stock pays a 0.64% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Graham Holdings Company Common Stock for 0 Days and Moderna, Inc. for 59 Days on average.
| GHC | MRNA | |
|---|---|---|
Market Cap | $4.97B | $86.33B |
Volume | 27,383 | 13,361,426 |
Sector | Industrials | Health |
52-Week High | $1.23K | $226.30 |
52-Week Low | $949.84 | $22.36 |
Typical Hold Time | 0 Days | 59 Days |
Enterprise Value | $5.06B | $82.48B |
Dividend Yield | 0.64% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Moderna (MRNA) trades at $226.30, up 5.88% with strong technical momentum as it joins the Nasdaq-100 index. Despite beating Q2 2026 EPS estimates, the company faces fundamental challenges with negative profitability margins (-142.58% net income margin) and declining revenue from pandemic peaks. Technical indicators show bullish momentum with price above key support levels, while analyst sentiment remains divided with a $115.70 consensus target well below current levels.
The outlook balances Nasdaq inclusion benefits against valuation concerns after a 500% 2026 rally. Investment opportunity lies in the cancer vaccine pipeline growth, while risks include sustained profitability challenges and high valuation multiples (P/S 38.5) that may not justify current price levels given declining revenue trends.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Graham Holdings Company is a diversified holding company with operations spanning education services (Kaplan), television broadcasting (Graham Media Group), healthcare services, and manufacturing, among other businesses; it was formerly known as The Washington Post Company.
Read more on GHC →Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →